- Home
- SER vs INKT Comparison
SER vs INKT Comparison
Compare SER & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- INKT
- Stock Information
- Founded
- SER 2017
- INKT 2017
- Country
- SER United States
- INKT United States
- Employees
- SER N/A
- INKT N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- SER Health Care
- INKT Health Care
- Exchange
- SER Nasdaq
- INKT Nasdaq
- Market Cap
- SER 56.5M
- INKT 48.7M
- IPO Year
- SER 2018
- INKT 2021
- Fundamental
- Price
- SER $5.40
- INKT $14.91
- Analyst Decision
- SER Strong Buy
- INKT Buy
- Analyst Count
- SER 2
- INKT 3
- Target Price
- SER $13.00
- INKT $37.50
- AVG Volume (30 Days)
- SER 25.7K
- INKT 201.7K
- Earning Date
- SER 08-11-2025
- INKT 08-14-2025
- Dividend Yield
- SER N/A
- INKT N/A
- EPS Growth
- SER N/A
- INKT N/A
- EPS
- SER N/A
- INKT N/A
- Revenue
- SER $130,000.00
- INKT N/A
- Revenue This Year
- SER N/A
- INKT N/A
- Revenue Next Year
- SER N/A
- INKT N/A
- P/E Ratio
- SER N/A
- INKT N/A
- Revenue Growth
- SER N/A
- INKT N/A
- 52 Week Low
- SER $3.81
- INKT $4.56
- 52 Week High
- SER $10.28
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- SER 48.70
- INKT 49.04
- Support Level
- SER $5.02
- INKT $13.10
- Resistance Level
- SER $5.63
- INKT $18.00
- Average True Range (ATR)
- SER 0.40
- INKT 2.10
- MACD
- SER 0.02
- INKT -0.26
- Stochastic Oscillator
- SER 29.03
- INKT 44.28
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.